Wave Life Sciences Ltd (NASDAQ: WVE) kicked off on Friday, down -6.68% from the previous trading day, before settling in for the closing price of $14.83. Over the past 52 weeks, WVE has traded in a range of $5.28-$21.73.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 34.27%. While this was happening, its average annual earnings per share was recorded -69.83%. With a float of $147.79 million, this company’s outstanding shares have now reached $160.29 million.
Wave Life Sciences Ltd (WVE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Wave Life Sciences Ltd is 19.24%, while institutional ownership is 75.44%. The most recent insider transaction that took place on Jan 02 ’26, was worth 150,260. In this transaction an insider of this company sold 9,375 shares at a rate of $16.03, taking the stock ownership to the 25,000 shares. Before that another transaction happened on Dec 11 ’25, when Company’s 10% Owner bought 1,470,000 for $19.00, making the entire transaction worth $27,930,000. This insider now owns 18,245,691 shares in total.
Wave Life Sciences Ltd (WVE) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.27 earnings per share (EPS), higher than consensus estimate (set at -0.22) by 0.5. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -69.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -19.18% during the next five years compared to 34.27% growth over the previous five years of trading.
Wave Life Sciences Ltd (NASDAQ: WVE) Trading Performance Indicators
Take a look at Wave Life Sciences Ltd’s (WVE) current performance indicators. Last quarter, stock had a quick ratio of 2.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.24 in one year’s time.
